WAKE-Up Pilot Study, Mental Training for patients with relapse-remitting multiple sclerosis and fatigue



Similar documents
Work-related diseases of occupational therapists - pilot study for creating an "occupational therapist-cohort" in Germany

Investigation of the effect of isomaltulose (PalatinoseTM) on metabolic parameters in subjects with Type 2 Diabetes.

Trial Description. Organizational Data. Secondary IDs

Prospective multicenter study for functional evaluation of transoral laser microsurgery (TLM) for supraglottic carcinomas - SUPRATOL

Stage A & C Sample Data Collection Form

Clinical Study Synopsis

OHTAC Recommendation

Submission Date: Project Start Date: Approximate Project End Date:

PLEASE NOTE: This study has been imported from ClinicalTrials.gov without additional data checks.

Efficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics

Survey of 267 Patients Using Low Dose Naltrexone for Multiple Sclerosis

Practice Guideline. Neuropsychological Evaluations

SLEEP DISTURBANCE AND PSYCHIATRIC DISORDERS

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal

Chemobrain. Halle C.F. Moore, MD The Cleveland Clinic October 3, 2015

1695 N.W. 9th Avenue, Suite 3302H Miami, FL Days and Hours: Monday Friday 8:30a.m. 6:00p.m. (305) (JMH, Downtown)

Practice Protocol. Neuropsychological Evaluations

Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 1 Updated November 10, 2009

Relapsing-remitting multiple sclerosis Ambulatory with or without aid

LONG TERM HYPERBARIC OXYGENATION (HBO) RETARDS PROGRESSION IN MULTIPLE SCLEROSIS PATIENTS

Mellen Center for Multiple Sclerosis

PCORI Workshop on Treatment for Multiple Sclerosis. Breakout Group Topics and Questions Draft

Limiting the Duration of Medication Assisted Treatment for Opioid Addiction: Will New State Policies Help or Hurt?

Multiple Sclerosis Society of Canada. CADA Presentation May 4, 2011

Instructions for Funding Authorization/Reauthorization Process. Residential Alcohol and Other Drug Treatment Programs

Version History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author

Fatigue in MS: 2005 update B. Colombo University of Milan - HSR

Issues Regarding Use of Placebo in MS Drug Trials. Peter Scott Chin, MD Novartis Pharmaceuticals Corporation

Psychological and Neuropsychological Testing

DMSRU Education Series 2012

Study Protocol Template

Biogen Global Medical Grants Office Multiple Sclerosis: Areas of Interest

PSYCHOLOGICAL AND NEUROPSYCHOLOGICAL TESTING

A blood sample will be collected annually for up to 2 years for JCV antibody testing.

MINISTERIO DE SALUD PUBLICA DIRECCION PROVINCIAL DE SALUD DEL GUAYAS HOSPITAL DE INFECTOLOGIA DR. JOSE DANIEL RODRIGUEZ MARIDUEÑA Guayaquil - Ecuador

Wellness for People with MS: What do we know about Diet, Exercise and Mood And what do we still need to learn? March 2015

NUVIGIL (armodafinil) oral tablet

Documentation Requirements ADHD

Montreal Cognitive Assessment (MoCA) Debbie Froese, B.M.R.-O.T., B.A. Christine Knight, Ph.D.,R.Psych.

Functional Specifications of the eztrial Clinical Trial Information Management System

DEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource

Pragmatic Evidence Based Review Substance Abuse in moderate to severe TBI

Acute Pain Management in the Opioid Dependent Patient. Maripat Welz-Bosna MSN, CRNP-BC

University of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol

FAA EXPERIENCE WITH NEUROPSYCHOLOGICAL TESTING FOR AIRMEN WITH DEPRESSION ON SSRI MEDICATIONS

Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) (APA, 2001) 10

Kaiser Permanente Southern California Depression Care Program

Objectives: Perform thorough assessment, and design and implement care plans on 12 or more seriously mentally ill addicted persons.

Trauma Insurance Claims Seminar Invitation

NSW Cancer Trials Network Network Portfolio Policy October 2012

Basic Results Database

NEUROPSYCHOLOGY QUESTIONNAIRE. (Please fill this out prior to your appointment and bring it with you.) Name: Date of appointment: Home address:

Mental Health and Substance Abuse Reporting Requirements Section 425 of P.A. 154 of 2005

Clinical Trials: Questions and Answers

MS an Mental Health. Alison Carolan MS Mental Health Nurse Kings College Hospital. IMPARTS December 2013

Cognitive behavioral therapy (CBT) may improve the home behavior of children with Attention Deficit/Hyperactivity Disorder (ADHD).

Immunex Corporation Novantrone (Mitoxantrone HCL) P&CNS Advisory Committee Briefing Document. Page 020

Oncology Nursing Society Annual Progress Report: 2008 Formula Grant

Canines and Childhood Cancer

Disease Modifying Therapies (DMTs) in Multiple Sclerosis

Study Design. Date: March 11, 2003 Reviewer: Jawahar Tiwari, Ph.D. Ellis Unger, M.D. Ghanshyam Gupta, Ph.D. Chief, Therapeutics Evaluation Branch

Cognitive Rehabilitation of Blast Traumatic Brain Injury

Diagnosis and Initial Management of Cognitive Disorders

The Relationship Between Anhedonia & Low Mood

Update on guidelines on biological treatment of depressive disorder. Dr. Henry CHEUNG Psychiatrist in private practice

ANXIETY & COGNITIVE IMPAIRMENT

If several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form.

A Phase II RCT of Stroke Navigators to Improve Compliance with Secondary Stroke Prevention: PROTECT DC

Oral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial

Fixing Mental Health Care in America

Clinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December Reference : NHSCB/D4/c/1

Depression and its Treatment in Older Adults. Gregory A. Hinrichsen, Ph.D. Geropsychologist New York City

Professional Reference Series Depression and Anxiety, Volume 1. Depression and Anxiety Prevention for Older Adults

CLINICAL PRACTICE GUIDELINES Treatment of Schizophrenia

Treatment of Low Risk MDS. Overview. Myelodysplastic Syndromes (MDS)

Technical Information

National Academy of Sciences Committee on Educational Interventions for Children with Autism

TESTING GUIDELINES PerformCare: HealthChoices. Guidelines for Psychological Testing

Self-management strategies for mild to moderate depression

See also for an online treatment course.

Assessment, Case Conceptualization, Diagnosis, and Treatment Planning Overview

To provide standardized Supervised Exercise Programs across the province.

Transcription:

PLEASE NOTE: This trial has been registered retrospectively. Trial Description Title WAKE-Up Pilot Study, Mental Training for patients with relapse-remitting multiple sclerosis and fatigue Trial Acronym [---]* URL of the trial [---]* Brief Summary in Lay Language 60 to 90% of all patients with relapse-remittign multiple sclerosis suffer from chronic fatigue symptoms and cognitive deficits. Tying up to the study of the research group Dr. Grossmann (Neurology 2010) we offer a mindfulness-based group training program to these patients. The training will be done for 6 weeks. Patients are randomized in group A and B. All Patients (group A and B) will undergo a neurological examination and a neuropsychological testing. Group A starts with the training. After the 6-week training all Patients (group A and B) will undergo again the neurological examination and the neuropsychological testing. Then group B starts with the training (cross-over design). After the 6- week training all Patients (group A and B) will undergo again the neurological examination and the neuropsychological testing. Brief Summary in Scientific Language Multiple Sclerosis is the neurological disease which leads most often to persisting impairments and early retirement in young adults. 60 to 90% of all MS patients suffer from fatigue, often in the early stages of the disease. For 15 to 50% of all MS patients, fatigue is of all symptoms the symptom disabling them the most in daily life, regardless of the degree of their physical impaiment. Paients suffer from uncontrollable fatigue, far worse from what they experienced before they were diagnosed with MS. As a consequence their participation in working life and social activities is extremely reduced. So far there is no medication available. Treatment with Amantadin or Modafinil can be discussed on an individual basis. A lot of treatment forms and interventions were tried, but not evaluated in scientific studies. There is a great need for studies which systematically investigate non-medication interventions. The research group of Dr. Grossmann (Neurology 75, 2010 pg 1141-1149) did a randomized-controlled study with 150 patients. Half of them received best medical treatment, half of them received a group training in addition to best medical treatment. They could prove that such a training can significantly improve quality of life. Tying to these results we offer a mindfulness-based group training program to these patients at the University Hospital of Freiburg, our department of neurology. Compared to the above mentioned study Page 1 of 5

we will include only patients with fatigue and we will train and test cognitive functions. Organizational Data DRKS-ID: DRKS00005500 Date of Registration in Partner Registry or other Primary Registry: [---]* Investigator Sponsored/Initiated Trial (IST/IIT): yes Ethics Approval/Approval of the Ethics Committee: Approved (leading) Ethics Committee Nr.: 224/13, Ethik-Kommission der Albert-Ludwigs-Universität Freiburg Secondary IDs Health condition or Problem studied ICD10: G35.1 - [generalization G35: Multiple sclerosis] Interventions/Observational Groups Arm 1: standard treatment plus a mindfulness-based group training (duration of 6 weeks, once a week for one hour), Arm 2: standard treatment (immunmodulatory medication, physiotherapy) Characteristics Study Type: Interventional Study Type Non-Interventional: [---]* Allocation: Randomized controlled trial Blinding: [---]* Who is blinded: [---]* Control: Active control Purpose: Treatment Assignment: Crossover Phase: N/A Off-label use (Zulassungsüberschreitende Anwendung eines Arzneimittels): N/A Page 2 of 5

Primary Outcome The training can significantly improve the patients' cognitive performance. This will be quanitified with standardized neuropsychological tests before and after 6-week-training: The d2-attention stress test and the VLMT verbal learn and memorizing test Secondary Outcome The training can significantly reduce the patients' fatigue symptoms and improve the patients'quality of life. This will be quanitified with standardized questionnaires: fatigue severity scale (FSS) and the SF-36 quality of life questionnaire. The Questionnaire will be filled out before and after the 6-week training Countries of recruitment DE Locations of Recruitment University Medical Center Neurologie, Freiburg im Breisgau Recruitment Planned/Actual: Actual (Anticipated or Actual) Date of First Enrollment: 2013/10/09 Target Sample Size: 34 Monocenter/Multicenter trial: Monocenter trial National/International: National Inclusion Criteria Gender: Both, male and female Minimum Age: 18 Years Maximum Age: 60 Years Additional Inclusion Criteria 1. The patient is willing to and physically and mentally capable to participate in the study 2. age 18 up to max. 60 years 3. confirmed diagnosis of relapse remitting multiple sclerosis, accordign McDonald criteria 2010 4. EDSS score of 0 up to max. 5.5 5. A diagnosis of achronic fatigue-syndrom as a symptom of MS (fatigue questionnaire Page 3 of 5

of the MS council as diagnostic tool) 6. severity of fatigue of at least 3 (Fatigue sverity scale) 7. if treatment with immunmodulatign medication, then for at least 6 weeks Exclusion criteria 1. no severe or untreated depression or psychiatric disease 2. no chronic sleep disturbances 3. no severe acute concomitant diseases which require acute medical treatment (e.g. tumor or encephalitis) 4. no untreated metabolism disease such as hypothyreosis or dysbalanced electrolytes 5. no anemia (Hb < 12g/dl) or known iron deficits 6. no intake of any sedating medication (analgetics containing opioid or antihistaminica with a sedating effect) 7. no relapse within the last 3 months Addresses Primary Sponsor Neurologische Universitätsklinik Freiburg Telephone: [---]* Fax: [---]* E-mail: [---]* URL: [---]* Contact for Scientific Queries Neurologische Universitätsklinik Ms. M.A. Gisa Schluh E-mail: gisa.schluh at uniklinik-freiburg.de Contact for Public Queries Neurologische Universitätsklinik Ms. M.A. Gisa Schluh E-mail: gisa.schluh at uniklinik-freiburg.de Page 4 of 5

Sources of Monetary or Material Support Institutional budget, no external funding (budget of sponsor/pi) Neurologische Universitätsklinik Freiburg Mr. Prof. Dr. Sebastian Rauer E-mail: [---]* Status Recruitment Status: Recruiting ongoing Study Closing (LPLV): [---]* Trial Publications, Results and other documents * This entry means the parameter is not applicable or has not been set. Page 5 of 5